Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

NCT06125652 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.

NCT NCT06125652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Lead sponsor
Xuzhou Medical University
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 4, 2023
Completion date
January 1, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia refractory, acute myeloid leukemia, in relapse